After a lengthy drought, could biotech M&A be on the upswing?
Radius, fending off activists, outlines pitch for $890 million buyout
Trio of biotechs raise funds to make enzymes and develop drugs for IBS and other autoimmune diseases
AbbVie dumps Alector's Alzheimer's immunotherapy after phase 1 review
*please scroll down for all the latest news*
